Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke

医学 特奈特普酶 溶栓 改良兰金量表 闭塞 冲程(发动机) 随机对照试验 纤溶剂 内科学 麻醉 组织纤溶酶原激活剂 缺血 缺血性中风 心肌梗塞 机械工程 工程类
作者
Bruce Campbell,Peter Mitchell,Leonid Churilov,Nawaf Yassi,Timothy Kleinig,Richard Dowling,Bernard Yan,Steven Bush,Vincent Thijs,Rebecca Scroop,Marion Simpson,Mark Brooks,Hamed Asadi,Teddy Y. Wu,Darshan Shah,Tissa Wijeratne,Henry Zhao,Fana Alemseged,Felix Ng,Peter Bailey
出处
期刊:JAMA [American Medical Association]
卷期号:323 (13): 1257-1257 被引量:227
标识
DOI:10.1001/jama.2020.1511
摘要

Importance

Intravenous thrombolysis with tenecteplase improves reperfusion prior to endovascular thrombectomy for ischemic stroke compared with alteplase.

Objective

To determine whether 0.40 mg/kg of tenecteplase safely improves reperfusion before endovascular thrombectomy vs 0.25 mg/kg of tenecteplase in patients with large vessel occlusion ischemic stroke.

Design, Setting, and Participants

Randomized clinical trial at 27 hospitals in Australia and 1 in New Zealand using open-label treatment and blinded assessment of radiological and clinical outcomes. Patients were enrolled from December 2017 to July 2019 with follow-up until October 2019. Adult patients (N = 300) with ischemic stroke due to occlusion of the intracranial internal carotid, \basilar, or middle cerebral artery were included less than 4.5 hours after symptom onset using standard intravenous thrombolysis eligibility criteria.

Interventions

Open-label tenecteplase at 0.40 mg/kg (maximum, 40 mg; n = 150) or 0.25 mg/kg (maximum, 25 mg; n = 150) given as a bolus before endovascular thrombectomy.

Main Outcomes and Measures

The primary outcome was reperfusion of greater than 50% of the involved ischemic territory prior to thrombectomy, assessed by consensus of 2 blinded neuroradiologists. Prespecified secondary outcomes were level of disability at day 90 (modified Rankin Scale [mRS] score; range, 0-6); mRS score of 0 to 1 (freedom from disability) or no change from baseline at 90 days; mRS score of 0 to 2 (functional independence) or no change from baseline at 90 days; substantial neurological improvement at 3 days; symptomatic intracranial hemorrhage within 36 hours; and all-cause death.

Results

All 300 patients who were randomized (mean age, 72.7 years; 141 [47%] women) completed the trial. The number of participants with greater than 50% reperfusion of the previously occluded vascular territory was 29 of 150 (19.3%) in the 0.40 mg/kg group vs 29 of 150 (19.3%) in the 0.25 mg/kg group (unadjusted risk difference, 0.0% [95% CI, −8.9% to −8.9%]; adjusted risk ratio, 1.03 [95% CI, 0.66-1.61];P = .89). Among the 6 secondary outcomes, there were no significant differences in any of the 4 functional outcomes between the 0.40 mg/kg and 0.25 mg/kg groups nor in all-cause deaths (26 [17%] vs 22 [15%]; unadjusted risk difference, 2.7% [95% CI, −5.6% to 11.0%]) or symptomatic intracranial hemorrhage (7 [4.7%] vs 2 [1.3%]; unadjusted risk difference, 3.3% [95% CI, −0.5% to 7.2%]).

Conclusions and Relevance

Among patients with large vessel occlusion ischemic stroke, a dose of 0.40 mg/kg, compared with 0.25 mg/kg, of tenecteplase did not significantly improve cerebral reperfusion prior to endovascular thrombectomy. The findings suggest that the 0.40-mg/kg dose of tenecteplase does not confer an advantage over the 0.25-mg/kg dose in patients with large vessel occlusion ischemic stroke in whom endovascular thrombectomy is planned.

Trial Registration

ClinicalTrials.gov Identifier:NCT03340493
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Supreme完成签到,获得积分10
1秒前
Laisy完成签到,获得积分10
1秒前
neao完成签到,获得积分10
1秒前
WXY完成签到,获得积分10
2秒前
桃花不换酒完成签到,获得积分10
2秒前
WL完成签到,获得积分20
3秒前
六月666完成签到,获得积分10
4秒前
Qyyy发布了新的文献求助10
5秒前
AIT完成签到,获得积分10
5秒前
优雅静珊完成签到,获得积分10
5秒前
缓慢新梅完成签到,获得积分10
5秒前
我不完成签到 ,获得积分10
6秒前
Eber完成签到,获得积分20
6秒前
小蚂蚁发布了新的文献求助10
6秒前
Peng完成签到,获得积分10
6秒前
7秒前
聚光灯下完成签到,获得积分10
8秒前
white完成签到,获得积分10
8秒前
WEILAI完成签到,获得积分10
8秒前
研友_VZG7GZ应助任性归尘采纳,获得10
8秒前
小强x完成签到,获得积分10
9秒前
9秒前
十一十八应助来日方长采纳,获得10
9秒前
9秒前
学学完成签到,获得积分10
9秒前
ding应助包子采纳,获得10
9秒前
9秒前
9秒前
10秒前
77完成签到,获得积分10
10秒前
忐忑的远山完成签到,获得积分10
11秒前
胖子完成签到,获得积分10
11秒前
12秒前
TWT完成签到,获得积分10
12秒前
牛肉汉堡完成签到,获得积分10
12秒前
自觉士萧完成签到,获得积分10
12秒前
Felix发布了新的文献求助10
13秒前
玉鱼儿完成签到 ,获得积分10
13秒前
ak完成签到,获得积分10
15秒前
gao发布了新的文献求助10
16秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968719
求助须知:如何正确求助?哪些是违规求助? 3513608
关于积分的说明 11168681
捐赠科研通 3248960
什么是DOI,文献DOI怎么找? 1794573
邀请新用户注册赠送积分活动 875194
科研通“疑难数据库(出版商)”最低求助积分说明 804716